VivoSim Labs, INC.
Close on Oct 19, 2026
- Market cap
- $825.22K
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2027 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Mar 31, 2025 | Apr 2, 2025 | Before market open | – | – | – |
| Q4 FY2019 Ended Mar 31, 2019 | May 22, 2019 | After market close | – | – | – |
| Q3 FY2019 Ended Dec 31, 2018 | Feb 7, 2019 | After market close | – | – | – |
| Q2 FY2019 Ended Sep 30, 2018 | Nov 8, 2018 | After market close | – | – | – |
| Q1 FY2019 Ended Jun 30, 2018 | Aug 9, 2018 | After market close | – | – | – |
| Q4 FY2018 Ended Mar 31, 2018 | May 31, 2018 | After market close | – | – | – |
| Q3 FY2018 Ended Dec 31, 2017 | Feb 8, 2018 | After market close | – | – | – |
| Q2 FY2018 Ended Sep 30, 2017 | Oct 4, 2017 | After market close | – | – | – |
| Q1 FY2018 Ended Jun 30, 2017 | Aug 9, 2017 | After market close | – | – | – |
| Q4 FY2017 Ended Mar 31, 2017 | Jun 7, 2017 | After market close | – | – | – |
| Q3 FY2017 Ended Dec 31, 2016 | Feb 9, 2017 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 6, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| revenue growth | Fiscal Year 2027 | 500% growth | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements VivoSim Labs filed with the SEC
VivoSim Provides Financial and Listing Compliance Update
Results of operations · EX-99.1 to Form 8-K
VivoSim Announces Pricing of $4.0 Million Private Placement Priced
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
VivoSim Announces Pricing of up to a $4 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
VivoSim Announces Emergence from Stealth Mode To Provide Technologies
Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
VivoSim to Carry Forward Organovo 3D Bioprinting
Regulation FD disclosure · EX-99.1 to Form 8-K
Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company
Acquisition or disposition completed · Executive or director change · Other events · EX-99.1 to Form 8-K
Organovo Announces Reverse Stock Split
Regulation FD disclosure · EX-99.1 to Form 8-K
Organovo Announces the Issuance of Additional Shares
Other events · EX-99.1 to Form 8-K
Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company
Material agreement · Listing notice · Other events · EX-99.1 to Form 8-K
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
INVESTOR PRESENTATION May 2024 NASDAQ: ONVO Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
ONVO Bioprinting Inflammatory Bowel Disease Model Cell expansion Intestinal Crypts Endothelial cells Smooth muscle cells Fibroblasts Cell Mixture Proprietary Media Matrix Multimodal Biocompatible Spatial control Complex Geometries Reproducible Scalable Cell dense Physiologically accurate biology
Regulation FD disclosure · EX-99.1 to Form 8-K
Organovo Announces Postponement of Annual Meeting of Stockholders
Other events · EX-99.1 to Form 8-K
Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K